What was Moderna's intraday high?

The stock hit a new 52-week high of $69.29.

How did Merck and Pfizer perform compared to Moderna?

Merck rose 2% to $128, and Pfizer rose 2%, while Moderna surged 14%.

What caused Moderna's stock to rise today?

No specific catalyst was mentioned, but it may reflect investor optimism about mRNA technology.

Moderna Surges 14%, Outperforming Merck and Pfizer on Friday

Moderna (MRNA) shares surged 14% to around $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally far exceeds gains of peer vaccine makers Merck (MRK) and Pfizer (PFE), which both rose 2%.

June 26, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

MRNA price

$68

MRNA 52 week high

$69.29

MRNA gain

14%

MRK price

$128

MRK gain

PFE price

not specified

PFE gain

Moderna (NASDAQ:MRNA) shares surged 14% to around $68 in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers.

Potential Reasons

The report did not specify a catalyst for the sharp rise, but the strong performance may reflect investor optimism about Moderna's mRNA technology and future growth prospects. Hitting a new 52-week high indicates strong positive momentum.

Context

Moderna stock is trading at $68, up 14% in the session. In comparison, Merck (NYSE:MRK) stock rose 2% to $128, while Pfizer (NYSE:PFE) stock traded up 2%. This divergence highlights investor focus on Moderna as a leader in mRNA technology.

Similar Moves in the Sector

The vaccine sector saw mixed moves, with Moderna significantly outperforming its peers. This could be due to company-specific developments or positive expectations for its pipeline.

Frequently Asked Questions

Moderna stock rose 14% to around $68.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.